It is currently only a preprint on bioRxiv, but it has already attracted significant attention from the scientific community and the journal Science. Mammoth Biosciences, a company founded by CRISPR co-inventor Jennifer Doudna, has developed NanoCas, a mini-editor that is just one-third the size of traditional gene-editing scissors (Cas9).
Continue reading
Don’t miss the lipid nanoparticles delivering CRISPR to the lungs (in Nature), the ever-growing CRISPR toolbox (in the CRISPR Journal), and the pig-monkey xenograft that brings experimentation on human patients closer (also in Nature).
The pandemic has accelerated progress in the field of lipid nanoparticles (LNP), and now CRISPR-based treatments are set to reap the benefits.
Continue reading
The Innovative Genomics Institute presents CRISPR Made Simple – the new online primer on gene editing made for kids or anyone starting from scratch.
The Broad Institute unveils SEND, a new delivery system inspired to retrotransposons (see Feng Zhang’s paper in Science)
Genotoxicity concerns: Nature Biotechnology explains how a cancer-associated phenomenon called chromothripsis could affect CRISPR therapies.
The Nobel Prize for CRISPR is one of the most exciting ever assigned in chemistry and one of the most celebrated in the media, for reasons related to the invention and the inventors alike. On the one hand, the technique is changing the practice and the image of genetic engineering. On the other hand, Jennifer Doudna and Emmanuelle Charpentier are not merely great scientists; they are a success story in cracking the glass ceiling and a symbol of the strength of collaboration.
Continue reading![nanoparticle MIT[1423]](https://mycrispr.blog/wp-content/uploads/2017/11/nanoparticle-mit1423.jpg)
Suppose you have developed the winning weapon to defeat certain genetic diseases by reliably correcting pathogenic mutations. There is still a problem: how do you march onto the battlefield, inside sick cells? The weapon is the genome-editing machinery, and the most efficient vessel ever tested are lipid nanoparticles. With this approach, described in a study published in Nature Biotechnology last week, CRISPR has beaten its success record in adult animals, knocking out the target gene in about 80% of liver cells. Continue reading
CRISPeR FRENZY 